IGF2BP2 (also known as Imp2) activates the PI3K/Akt signaling pathway and thereby promotes glioma progression, whereas its inhibition sensitizes glioma cells to temozolomide treatment (Mu et al., 2015). Here, AKT1 is linked to central nervous system cancer.